Taconic Biosciences
Taconic Biosciences, a leading provider of genetically engineered rodent models, is headquartered in the United States, with significant operations across Europe and Asia. Founded in 2007, the company has established itself as a key player in the biotechnology industry, focusing on preclinical research and model development for drug discovery and development. Taconic's core offerings include custom mouse models, biorepositories, and advanced breeding services, all designed to meet the specific needs of researchers in academia and the pharmaceutical sector. What sets Taconic apart is its commitment to quality and innovation, ensuring that their models are not only reliable but also tailored to the unique requirements of each project. With a strong market position, Taconic Biosciences has achieved notable milestones, including partnerships with leading pharmaceutical companies and contributions to significant scientific advancements. Their dedication to excellence continues to drive their reputation as a trusted resource in the field of biomedical research.
DitchCarbon Score
How does Taconic Biosciences's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Taconic Biosciences's score of 23 is lower than 66% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Taconic Biosciences's reported carbon emissions
Taconic Biosciences, headquartered in the United States, currently does not report any specific carbon emissions data, as indicated by the absence of emissions figures in kg CO2e. However, the company is committed to addressing climate change through its near-term targets, which are classified as "Committed" under the Science Based Targets initiative (SBTi). While Taconic Biosciences has not set a net-zero target, it is actively engaged in initiatives aimed at reducing its carbon footprint within the pharmaceuticals, biotechnology, and life sciences sector. The company has not disclosed specific reduction targets or achievements, but its commitment to the SBTi reflects a proactive approach to climate action. As of December 2023, Taconic's climate commitments are aligned with industry standards, demonstrating a recognition of the importance of sustainability in its operations. The absence of emissions data does not diminish the company's dedication to improving its environmental impact in the future.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Taconic Biosciences is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
